(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1 Ibrutinib Intermediate Purity >99.0% (GC)
Chemical Name | (S)-1-Boc-3-Hydroxypiperidine |
Synonyms | (S)-1-(tert-Butoxycarbonyl)-3-Hydroxypiperidine; (S)-1-Boc-3-Piperidinol |
CAS Number | 143900-44-1 |
CAT Number | RF-CC299 |
Stock Status | In Stock, Production Capacity 20 Tons/Month |
Molecular Formula | C10H19NO3 |
Molecular Weight | 201.27 |
Melting Point | 52.0~56.0℃ |
Solubility | Soluble in Methanol |
Specific Rotation [a]20/D | +9.0°~+11.0° (C=1 in Chloroform) |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White Powder or Crystals |
Chiral Purity | >99.5% (GC) |
Chemical Purity | >99.5% (GC) |
Water (K.F) | ≤0.50% |
Methanol (GC) | ≤50ppm |
Ethanol (GC) | ≤50ppm |
DCM (GC) | ≤500ppm |
3-Hydroxypiperidine | ≤0.10% |
3-Hydroxypyridine | ≤0.20% |
1-Boc-3-Piperidone | ≤0.10% |
1-Boc-4-Hydroxypiperidine | ≤0.10% |
1.96 RRT | ≤0.20% |
Any Unspecified Impurity | ≤0.10% |
Test Standard | Enterprise Standard |
Usage | Pharmaceutical Intermediates; Chiral Compounds |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
(S)-1-Boc-3-Hydroxypiperidine (CAS: 143900-44-1) is an important chiral intermediate for the synthesis of Ibrutinib (CAS: 936563-96-1). Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.
-
4-Phenoxyphenylboronic Acid CAS 51067-38-0 Ibru...
-
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1 I...
-
Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC) API
-
Ibrutinib Deacryloylpiperidine CAS 330786-24-8 ...
-
Ibrutinib Intermediate CAS 330792-70-6 Purity >...
-
(S)-1-Boc-3-Hydroxypyrrolidine CAS 101469-92-5 ...
-
(R)-1-Boc-3-Hydroxypyrrolidine CAS 109431-87-0 ...
-
(S)-1-Boc-Piperazine-2-Carboxylic Acid CAS 1595...
-
(R)-1-Boc-Piperazine-2-Carboxylic Acid CAS 2787...
-
4-Amino-3-Iodo-1H-Pyrazolo[3,4-d]pyrimidine CAS...
-
1-Boc-3-Hydroxypiperidine CAS 85275-45-2 Ibruti...
-
3-Hydroxypiperidine CAS 6859-99-0 Ibrutinib Int...
-
4-Aminopyrazolo[3,4-d]pyrimidine CAS 2380-63-4 ...
-
4-Phenoxybenzoic Acid CAS 2215-77-2 Ibrutinib I...